Cholesterol Regulation of Inflammatory Macrophages in Atherosclerosis
动脉粥样硬化中炎症巨噬细胞的胆固醇调节
基本信息
- 批准号:10188606
- 负责人:
- 金额:$ 35.12万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2017
- 资助国家:美国
- 起止时间:2017-08-01 至 2022-05-31
- 项目状态:已结题
- 来源:
- 关键词:AdhesionsAntibodiesApolipoprotein A-IApolipoproteins BArterial Fatty StreakAtherosclerosisB-LymphocytesBinding ProteinsBiological MarkersBlocking AntibodiesBlood VesselsCardiovascular DiseasesCardiovascular systemCell CommunicationCell membraneCell physiologyCellsCholesterolCholesterol EstersClinicDependovirusDevelopmentDiagnosticDiagnostic testsDimerizationDiseaseEndothelial CellsEpitopesEventExcisionFoam CellsGenesGoalsHigh Density LipoproteinsHumanImmuneImmunoglobulin MIn VitroInflammationInflammatoryInflammatory ResponseInfusion proceduresLaboratoriesLipidsLipoproteinsLow-Density LipoproteinsMacrophage ActivationMeasuresMediatingMembrane MicrodomainsMonoclonal AntibodiesMulti-Ethnic Study of AtherosclerosisMusMyocardial InfarctionNamesOxidesPatientsPhenotypePlasmaPlasma ProteinsPopulationProcessProtein DeficiencyRecombinant ProteinsRecombinantsRegulationResearchResearch PersonnelRuptureSamplingStrokeStudy modelsT-LymphocyteTLR4 geneTestingTherapeuticTissuesTranslatingatheroprotectivecoronary artery calciumexperienceexperimental studyhuman studyhypercholesterolemiaimmunoregulationimprovedin vivo evaluationmacrophagemonocytemouse modelnovelnovel therapeutic interventionoxidationprognostic valueprotein biomarkersresponsevascular inflammation
项目摘要
Project Summary
Hypercholesterolemia and vascular inflammation are among the strongest causative factors in the
development of atherosclerosis and in the progression of early atherosclerotic lesions into advanced
vulnerable plaques. However, it is yet unclear whether vascular cholesterol accumulation directly contributes to
vascular inflammation and, specifically, to polarization of macrophages into inflammatory phenotypes. In this
project, we will investigate two mechanisms, which contribute to cholesterol-mediated inflammatory responses
by macrophages, and will determine their quantitative significance in the development of atherosclerosis in a
mouse model and the translational potential of relevant new biomarkers and therapeutic approaches. In an
atherogenic mechanism, oxidized cholesteryl esters (OxCE) induce dimerization of toll-like receptor-4 (TLR4),
which in turn mediates inflammatory and atherogenic responses in macrophages. In an atheroprotective
mechanism, we have identified the secreted apoA-I binding protein (AIBP) as a factor, which significantly
improves HDL function by accelerating cholesterol efflux, resulting in the disruption of lipid raft-dependent
TLR4 dimerization and reduced inflammatory responses in macrophages. We will test the hypotheses that
OxCE promotes and AIBP inhibits inflammatory macrophage polarization, foam cell formation and
atherosclerosis. We have generated a monoclonal antibody blocking OxCE, as well as systemic and
macrophage-specific Apoa1bp-/- mice to test these hypotheses. In complementary experiments, we will use
infusions of recombinant AIBP and/or an AIBP-expressing adeno-associated virus to achieve increased AIBP
levels in plasma and expect to inhibit atherosclerosis progression. Importantly, synergistic studies with other
PPG Projects will examine the relevance of OxCE and AIBP mechanisms to atherogenic or atheroprotective
functions of different monocyte and T and B cell populations. To translate our findings into clinic, we will use
plasma from Multi-Ethnic Study of Atherosclerosis (MESA) subjects, who have elevated coronary artery
calcium or have experienced major adverse cardiovascular events, to evaluate diagnostic and prognostic value
of new OxCE and AIBP biomarkers. These results will be integrated with other biomarkers identified by the
PPG Investigators. To examine novel therapeutic approaches to restrain cholesterol-induced inflammation, we
will test the hypothesis that raising AIBP in the low-AIBP plasma and blocking OxCE in the high-OxCE plasma
found in MESA populations will reduce plasma's atherogenic effects on human macrophages. The proposed
studies will enhance our mechanistic understanding of cholesterol-mediated inflammation in atherosclerosis
and will advance new biomarker and therapeutic strategies for cardiovascular disease.
项目摘要
高胆固醇血症和血管炎症是最强的致病因素之一,
动脉粥样硬化的发展和早期动脉粥样硬化病变进展到晚期
脆弱的斑块然而,目前尚不清楚血管胆固醇积累是否直接有助于
血管炎症,特别是巨噬细胞极化成炎性表型。在这
本研究将探讨胆固醇介导的炎症反应的两种机制
巨噬细胞,并将确定其在动脉粥样硬化的发展中的定量意义,
小鼠模型以及相关新生物标志物和治疗方法的转化潜力。中
氧化胆固醇酯(OxCE)诱导Toll样受体4(TLR 4)的二聚化,
其又介导巨噬细胞中的炎症和致动脉粥样硬化反应。在一个动脉粥样硬化保护
机制,我们已经确定了分泌的apoA-I结合蛋白(AIBP)作为一个因素,
通过加速胆固醇流出改善HDL功能,导致脂筏依赖性
TLR 4二聚化和减少巨噬细胞中的炎症反应。我们将测试假设,
OxCE促进和AIBP抑制炎性巨噬细胞极化,泡沫细胞形成和炎症性巨噬细胞增殖。
动脉粥样硬化我们已经产生了阻断OxCE的单克隆抗体,以及全身性和全身性抑制剂。
巨噬细胞特异性Apoa 1bp-/-小鼠来测试这些假设。在补充实验中,我们将使用
输注重组AIBP和/或表达AIBP的腺相关病毒以实现增加的AIBP
在血浆中的水平,并期望抑制动脉粥样硬化进展。重要的是,协同研究与其他
PPG项目将检查OxCE和AIBP机制与致动脉粥样硬化或动脉粥样硬化保护的相关性
不同单核细胞和T及B细胞群的功能。为了将我们的发现转化为临床,我们将使用
来自冠状动脉升高的多种族动脉粥样硬化研究(梅萨)受试者的血浆
钙或经历过主要不良心血管事件,以评估诊断和预后价值
新的OxCE和AIBP生物标志物。这些结果将与其他生物标志物进行整合,
PPG研究者。为了研究抑制胆固醇诱导的炎症的新治疗方法,我们
将检验在低AIBP血浆中升高AIBP和在高OxCE血浆中阻断OxCE的假设
在梅萨人群中发现的抗动脉粥样硬化药物将减少血浆对人类巨噬细胞的致动脉粥样硬化作用。拟议
研究将增强我们对动脉粥样硬化中胆固醇介导的炎症机制的理解
并将为心血管疾病提供新的生物标志物和治疗策略。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Yury Miller其他文献
Yury Miller的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Yury Miller', 18)}}的其他基金
Reversal of preexisting neuropathic pain by spinal delivery of AIBP
通过脊髓输送 AIBP 逆转先前存在的神经性疼痛
- 批准号:
9750836 - 财政年份:2018
- 资助金额:
$ 35.12万 - 项目类别:
Reversal of preexisting neuropathic pain by spinal delivery of AIBP
通过脊髓输送 AIBP 逆转先前存在的神经性疼痛
- 批准号:
10197482 - 财政年份:2018
- 资助金额:
$ 35.12万 - 项目类别:
Project 2: Cholesterol Regulation of Inflammatory Macrophages in Atherosclerosis
项目2:动脉粥样硬化中炎症巨噬细胞的胆固醇调节
- 批准号:
10334095 - 财政年份:2017
- 资助金额:
$ 35.12万 - 项目类别:
Early Forms of Oxidized LDL, TLRs and Atherosclerosis
氧化 LDL、TLR 和动脉粥样硬化的早期形式
- 批准号:
7839765 - 财政年份:2009
- 资助金额:
$ 35.12万 - 项目类别:
相似海外基金
University of Aberdeen and Vertebrate Antibodies Limited KTP 23_24 R1
阿伯丁大学和脊椎动物抗体有限公司 KTP 23_24 R1
- 批准号:
10073243 - 财政年份:2024
- 资助金额:
$ 35.12万 - 项目类别:
Knowledge Transfer Partnership
Role of Natural Antibodies and B1 cells in Fibroproliferative Lung Disease
天然抗体和 B1 细胞在纤维增生性肺病中的作用
- 批准号:
10752129 - 财政年份:2024
- 资助金额:
$ 35.12万 - 项目类别:
CAREER: Next-generation protease inhibitor discovery with chemically diversified antibodies
职业:利用化学多样化的抗体发现下一代蛋白酶抑制剂
- 批准号:
2339201 - 财政年份:2024
- 资助金额:
$ 35.12万 - 项目类别:
Continuing Grant
Isolation and characterisation of monoclonal antibodies for the treatment or prevention of antibiotic resistant Acinetobacter baumannii infections
用于治疗或预防抗生素耐药鲍曼不动杆菌感染的单克隆抗体的分离和表征
- 批准号:
MR/Y008693/1 - 财政年份:2024
- 资助金额:
$ 35.12万 - 项目类别:
Research Grant
Developing first-in-class aggregation-specific antibodies for a severe genetic neurological disease
开发针对严重遗传神经系统疾病的一流聚集特异性抗体
- 批准号:
10076445 - 财政年份:2023
- 资助金额:
$ 35.12万 - 项目类别:
Grant for R&D
Discovery of novel nodal antibodies in the central nervous system demyelinating diseases and elucidation of the mechanisms through an optic nerve demyelination model
发现中枢神经系统脱髓鞘疾病中的新型节点抗体并通过视神经脱髓鞘模型阐明其机制
- 批准号:
23K14783 - 财政年份:2023
- 资助金额:
$ 35.12万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Elucidation of the mechanisms controlling the physicochemical properties and functions of supercharged antibodies and development of their applications
阐明控制超电荷抗体的理化性质和功能的机制及其应用开发
- 批准号:
23KJ0394 - 财政年份:2023
- 资助金额:
$ 35.12万 - 项目类别:
Grant-in-Aid for JSPS Fellows
Role of antibodies in hepatitis E virus infection
抗体在戊型肝炎病毒感染中的作用
- 批准号:
10639161 - 财政年份:2023
- 资助金额:
$ 35.12万 - 项目类别:
Defining the protective or pathologic role of antibodies in Post-Ebola Syndrome
定义抗体在埃博拉后综合症中的保护或病理作用
- 批准号:
10752441 - 财政年份:2023
- 资助金额:
$ 35.12万 - 项目类别:
Human CMV monoclonal antibodies as therapeutics to inhibit virus infection and dissemination
人 CMV 单克隆抗体作为抑制病毒感染和传播的治疗药物
- 批准号:
10867639 - 财政年份:2023
- 资助金额:
$ 35.12万 - 项目类别: